Sodium-glucose cotransporter inhibitors and oxidative stress: An update.
J Cell Physiol
; 234(4): 3231-3237, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30443936
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are therapeutic agents that have been used recently to reduce tubular absorption of glucose, leading to enhanced glycosuria, resulting in the reduction of blood glucose and improved diabetes control. Recent data suggest that SGLT2 inhibitors have antioxidant properties that may be key to the reduction in cardiovascular death found in clinical trials. Oxidative stress is involved in the development and progression of atherosclerosis, as well as underlying diabetes complications, and may result from either increased free-radical production, a reduction in antioxidative capacity, or a combination of both. In this report, we have reviewed the recent evidence of the impact that SGLT2 inhibition may have on improved oxidative stress by either amelioration of free-radical generation or potentiation of cellular antioxidative capacity, and its importance in the prevention of cardiovascular and diabetes complications.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Glicemia
/
Doenças Cardiovasculares
/
Espécies Reativas de Oxigênio
/
Estresse Oxidativo
/
Diabetes Mellitus
/
Transportador 2 de Glucose-Sódio
/
Inibidores do Transportador 2 de Sódio-Glicose
/
Antioxidantes
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Cell Physiol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Irã